Kartik Sehgal

机构：Brigham and Women's Hospital, Harvard University, Indian Institute of Information Technology Guwahati, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center · ORCID：0000-0003-4391-6943

发表论文 215 篇 · 总被引 10175 次 · h-index 24

代表论文

• First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 2)
• Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial (2026 · Nature Communications · 被引 1)
• Preliminary Safety and Efficacy of Tarlatamab in Medullary Thyroid Carcinoma (2026 · JCO oncology advances. · 被引 1)
• A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer (2025 · Cancer Immunology Immunotherapy · 被引 1)
• Combination multikinase inhibition and checkpoint blockade in RAIR DTC (2026 · Annals of Thyroid)
• Table S2 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA (2026)